Loading organizations...
Soufflé Therapeutics develops nucleic acid medicines designed to precisely target and enter specific cells responsible for disease. The company engineers cell-specific ligands to deliver siRNA-based therapeutics with high precision, ensuring the medicines are accurately transferred across cell membranes to their intended targets. This approach combines proprietary technologies for receptor identification, ligand optimization, and potent siRNA engineering to create more effective, safer, and durable treatments.
The company was founded by a team including Amir Nashat, Susan Langer, and Vadim Dudkin, drawing on deep expertise in genetic medicine. Roman Bogorad also joined as Founding Head of Discovery Biology in 2021, with connections to Professor Robert Langer's lab, indicating the scientific heritage behind the venture. The foundational insight stemmed from the realization that nucleic acid medicines could modulate gene and protein levels to reverse disease, and Soufflé aimed to deliver this capability with unprecedented cellular precision.
Soufflé Therapeutics focuses its efforts on patients suffering from muscle dystrophies, heart failure, and metabolic disorders, with initial programs addressing Facioscapulohumeral Muscular Dystrophy (FSHD) and genetically-driven cardiomyopathies. The company's vision is to redefine medicine creation by designing potent, precise, and safe therapies for a broad spectrum of diseases, continuously expanding its preclinical pipeline across various cell and tissue types to meet significant patient needs.
Soufflé Therapeutics has raised $200.0M across 1 funding round.
Soufflé Therapeutics has raised $200.0M in total across 1 funding round.
Soufflé Therapeutics has raised $200.0M across 1 funding round. Most recently, it raised $200.0M Series A in December 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 1, 2024 | $200M Series A | Andrew Hedin | ARCH Venture Partners, Polaris Partners, Helen KIM | Announced |
Soufflé Therapeutics has raised $200.0M in total across 1 funding round.
Soufflé Therapeutics's investors include Andrew Hedin, ARCH Venture Partners, Polaris Partners, Helen Kim.
Soufflé Therapeutics is a biotechnology company developing cell-specific nucleic acid medicines, primarily siRNA-based therapies, using proprietary technologies for ligand optimization and siRNA engineering to target specific cell types like skeletal muscle cells and cardiomyocytes.[1][2][3] It addresses unmet needs in muscular dystrophies (e.g., facioscapulohumeral muscular dystrophy or FSHD), heart failure, metabolic disorders, and phospholamban (PLN) gene-related cardiomyopathies by delivering potent, long-lasting treatments beyond the liver.[1][3][5] The company serves patients with these rare and chronic diseases, solving the longstanding challenge of precise genetic medicine delivery to non-liver cells.[1][3] Founded in 2022, Soufflé raised a $200 million Series A in 2024 from investors like Bessemer Venture Partners, Arch Venture Partners, and others, plus over $3.5 billion in Big Pharma partnerships with AbbVie, Amgen, Bayer, and Novo Nordisk; its lead FSHD program is slated for clinical trials in 2026, signaling strong early momentum.[3][4][5]
Soufflé Therapeutics was founded in 2022 by a team of MIT luminaries and biotech veterans, including Robert Langer (MIT professor and prolific inventor in drug delivery and gene therapy), Daniel Anderson (MIT professor), Brad Pentelute (MIT professor), and Victor Kotelianski (former Alnylam SVP who co-invented siRNA drug Leqvio).[1][3][5] The idea emerged from decades of research tackling the challenge of delivering genetic medicines to extrahepatic cells, with Langer emphasizing that "Soufflé can now achieve this" through combined ligand and siRNA technologies.[1][3] It's a family affair: Robert's daughter Susan Langer serves as Chief Business Officer and founding president, bringing experience from Biogen and startups like Paratus Sciences, while his son Michael Langer (via his VC firm T.Rx) confirmed the massive Series A.[1][3][5] CEO Amir Nashat, a Langer lab alum and biotech leader, leads the effort, with early traction from Big Pharma partnerships and $3.5 billion in commitments shortly after launch.[3][5]
Soufflé rides the wave of advanced RNA therapeutics, expanding siRNA beyond liver targets amid surging demand for precision genetic medicines in rare diseases and cardiology.[1][3][5] Timing is ideal post-approvals like Leqvio, with market forces favoring platforms solving delivery hurdles—valued at billions in unmet needs for FSHD (orphan disease) and heart failure.[1][5] By partnering with Big Pharma early, Soufflé influences the ecosystem, accelerating de-risked development and potentially standardizing cell-specific delivery, much like Alnylam's liver siRNA breakthroughs.[3][5]
Soufflé is poised for clinic entry in 2026 with its FSHD lead, expanding preclinical programs in metabolism and cardiomyopathies amid RNA tech maturation.[3][5] Trends like AI-driven ligand design and multi-modal partnerships will propel growth, evolving its influence from pioneer platform to multi-asset biotech powerhouse. As Robert Langer's legacy in delivery tech meets Big Pharma scale, Soufflé redefines targeted medicines, fulfilling its promise to treat diseases once out of reach.[1][3]
